• Recruiting

NCT02199665: Phase 1: Selinexor, Carfilzomib, & Dexamethasone in Treating Patients With RRMM (SINE)

Updated: Jun 22

Multiple Myeloma Research Consortium


NCT02199665: Phase 1: Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)

Seli-Kd

sine

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma (SINE)


This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, such as selinexor and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving selinexor, carfilzomib, and dexamethasone may be a better treatment for multiple myeloma.


Sponsor:

University of Chicago


Collaborator:

National Cancer Institute (NCI)


Multiple Locations

 

ClinicalTrials.gov Identifier: NCT02199665


Official Title: A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With Carfilzomib and Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

First Posted: July 24, 2014


Click here to see details on ClinicalTrials.gov

 

Drug: selinexor

Drug: carfilzomib

Drug: dexamethasone

 

Phase 1 study of selinexor plus carfilzomib and dexamethasone for the treatment of relapsed/refractory multiple myeloma

Br J Haematol; 2019

https://pubmed.ncbi.nlm.nih.gov/31124580/

 

Locations

United States, Arizona

United States, Illinois

United States, Michigan

United States, New York







Posts Archive